#United States #New York #Securities Fraud #Pomerantz LLP #Agios Pharmaceuticals

Pomerantz Law Firm Launches Investigation for Agios Pharmaceuticals Investors

On September 8, 2025, Pomerantz LLP—a leading firm renowned for its work in corporate lawsuits—announced that it is probing potential claims against Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). This investigation comes amid concerns that Agios and its management may have engaged in securities fraud and other illegal business activities.

Investors of Agios are advised to reach out to Danielle Peyton, an attorney at Pomerantz, at [email protected] or via phone at 646-581-9980, ext. 7980, to discuss their experiences and explore their options. The focus of this investigation centers on Agios's recent press release revealing that the U.S. Food and Drug Administration (FDA) has postponed the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) for its product, PYRUKYND® (mitapivat).

Impact of the FDA Announcement

On September 4, 2025, Agios made headlines by disclosing an extension of the FDA's review process, with the PDUFA date now moved to December 7, 2025. This announcement sent ripples through the market, causing Agios’s stock to plummet by $4.48, equating to an 11.03% drop, closing at $36.13 per share the same day. Such volatility raised eyebrows among investors and sparked suspicions regarding transparency and communication practices by the company.

Pomerantz LLP is recognized as one of the premier firms specializing in corporate and securities litigation, and it's particularly notable for its commitment to protecting the rights of shareholders. Founded by Abraham L. Pomerantz—often referred to as the dean of the class action bar—the firm has made substantial contributions to combating securities fraud over the past 80 years. With a history of recovering significant compensations for victims of corporate misconduct, Pomerantz aims to uphold its founder's legacy by pursuing justice for Agios investors who may have been adversely affected by the recent developments.

Agios Pharmaceuticals: Company Background

Agios Pharmaceuticals is known for producing innovative therapies to treat severe genetic diseases and cancer. The company's flagship product, PYRUKYND®, has shown promise for treating patients suffering from thalassemia, a group of blood disorders. As such, news regarding its FDA approval is critically important not just to Agios, but to countless patients who rely on its therapies.

In light of the ongoing investigation, potential investors should consider the implications of these recent developments. With significant legal battles ahead and a pending FDA review that may affect Agios's future, the atmosphere surrounding the company remains charged with uncertainty. Investors are encouraged to stay informed and proactive in reaching out to legal counsel if they believe their rights may have been infringed.

Moving Forward

As Pomerantz Law Firm continues its investigation, it strives to ascertain whether Agios and its personnel acted unlawfully. Given the stakes involved and the potential ramifications for both the company and its shareholders, those affected are urged to join the inquiry, gather information, and understand their legal rights.

For further details on the investigation or to participate in the class action, interested parties can visit Pomerantz’s official website at www.pomerantzlaw.com. With their extensive experience and unwavering commitment to shareholder advocacy, Pomerantz LLP is poised to play a crucial role in ensuring accountability at Agios Pharmaceuticals during this tumultuous period.